Mail & Guardian
Mail & Guardian
gilead scienceslatest news & developments
What’s the best way to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what modelling data shows. (Pexels, kaboompics)
ANTIRETROVIRAL DRUGS

180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough

The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics.…

  • Linda Pretorius
9 min read
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in. We spoke to Mitchell Warren from the New York HIV advocacy organisation, Avac, to find out what that means for South Africa. Photo: Paul Botes
AVAC

What will HIV funding look like in 2026?

After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in

  • Mia Malan
  • Tanya Pampalone
9 min read
South Africa’s first consignment of lenacapavir (LEN), the twice-yearly anti-HIV injection, arrived at OR Tambo International Airport last week. Photo: Mufid Majnun/Unsplash
ANTIRETROVIRAL DRUGS

SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them

Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?

  • Linda Pretorius
  • Jacques Verryn
11 min read
One in 10 clinics in South Africa will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines regulator, Sahpra, says it’s on track to announce its registration decision within the next few days, by the end of October. So who should get LEN first? (Anna-Maria van Niekerk)
AARON MOTSOALEDI

The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses?

The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October

  • Mia Malan
10 min read
Two Indian generic drugmakers — Hetero and Dr Reddy’s — will be funded by the Gates Foundation and Unitaid, respectively, to produce and sell the twice-a-year anti-HIV shot around R692 per person per year. (Anna-Maria van Niekerk)
ANTIRETROVIRAL DRUGS

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill

Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year

  • Mia Malan
9 min read
The health department anticipates that it could start to use government money to buy cheaper generics of anti-HIV jab the lenacapvir by April 2027. (Unsplash)
AARON MOTSOALEDI

SA plans anti-HIV jab roll-out at hundreds of clinics by April

The health department hopes to make the twice-a-year anti-HIV injection lenacapavir available soon and to be buying generics by 2027

  • Mia Malan
11 min read
Research indicates the anti-HIV jab, lenacapavir, protects women completely and works almost as well for men, transgender and nonbinary people. Photo: Marko Milivojevic/Pixnio
ANTIRETROVIRAL DRUGS

SA gets R520 million to buy the twice-a-year anti-HIV jab – but there’s a snag

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it has already been awarded and was cut by 16% in June

  • Mia Malan
8 min read